[Clinical and Pathological Features of Blastic Plasmacytoid Dendritic Cell Neoplasm].
The immunophenotype of BPDCN is heterogeneous. CD56 is a reliable marker to distinguish neoplastic pDC cells from reactive pDC cells. The BPDCN patients who underwent hematopoietic stem cell transplantation (HSCT) after achieving remission from initial chemotherapy tend to have a better prognosis.
Authors
- Hongyan Liao (ORCID: https://orcid.org/0000-0002-8713-6896)
- Xin Zhang (ORCID: https://orcid.org/0000-0001-6812-7356)
- Ying Yang (ORCID: https://orcid.org/0000-0003-4758-1917)
Institutions
- Sichuan University (CN)
- West China Hospital of Sichuan University (CN)
Publication Details
- Journal
- PubMed
- Published
- 2024-12-01
- DOI
- https://doi.org/10.19746/j.cnki.issn.1009-2137.2024.06.002
- Primary Topic
- Cutaneous lymphoproliferative disorders research
- Type
- article